ライフサイエンスコーパス: diabetes

1 Childhood-onset type 1 diabetes.

2 he effect of immune interventions for type 1 diabetes.

3 te to glucolipotoxicity that leads to type 2 diabetes.

4 signaling in islets from donors with type 2 diabetes.

5 tissue of primary pathogenic importance for diabetes.

6 iseases, Alzheimer disease, pancreatitis and diabetes.

7 bohydrate foods are linked to higher risk of diabetes.

8 ch as those caused by hypoxia, ischemia, and diabetes.

9 ain normoglycemia in a mouse model of type 1 diabetes.

10 (PI-CF) are at increased risk for developing diabetes.

11 s a tentative surrogate imaging biomarker in diabetes.

12 promoting bone regeneration in patients with diabetes.

13 s were observed in patients with and without diabetes.

14 ciation between serum potassium and incident diabetes.

15 n peripheral blood in the etiology of type 2 diabetes.

16 ed data from 109,385 patients with new-onset diabetes.

17 amylin), the protein associated with type II diabetes.

18 a strong agonist insulin mimetope in type 1 diabetes.

19 AF and normalize glucose sensing after RH in diabetes.

20 ve as potential drug targets to treat type 2 diabetes.

21 othesis using the NOD murine model of type 1 diabetes.

22 to the loss of functional beta cell mass in diabetes.

23 R) with incident CVD in patients with type 2 diabetes.

24 vascular complications in adults with type 2 diabetes.

25 associated with an increased risk of type 2 diabetes.

26 Mll1 compared with control subjects without diabetes.

27 lated functional burden among US adults with diabetes.

28 enhance GLP-1 levels in patients with type 2 diabetes.

29 iated outcomes among post-CABG patients with diabetes.

30 ften induce excessive weight gain and type 2 diabetes.

31 s in the pharmacological treatment of type 2 diabetes.

32 insights into the pathophysiology of type 2 diabetes.

33 a Y1 receptor antagonist delays the onset of diabetes.

34 ed with HLA-matched control subjects without diabetes.

35 e prevention of metabolic syndrome or type 2 diabetes.

36 ogressive deterioration of beta-cell mass in diabetes.

37 etes of the young form 3 (MODY 3) and type 2 diabetes.

38 in this continuously insured population with diabetes.

39 arget for vascular prevention in obesity and diabetes.

40 iciency in the NOD mouse model of autoimmune diabetes.

41 associated with subsequent susceptibility to diabetes.

42 ecretory protein and a novel risk factor for diabetes.

43 Of these patients, most (98%) had type 2 diabetes.

44 reasingly being used as treatment for type 2 diabetes.

45 ed to improve the treatment of patients with diabetes.

46 with an increased risk of developing type 2 diabetes.

47 chronic disorders such as obesity and type 2 diabetes.

48 targets for the prevention and treatment of diabetes.

49 in the dietary prevention and management of diabetes.

50 echanisms modulating later susceptibility to diabetes.

51 s amputation stump healing in the setting of diabetes.

52 gful change in BMI among adult patients with diabetes.

53 hibitor approved for the treatment of type 2 diabetes.

54 e and 1.37 (1.03-1.82; P = 0.021) for type 2 diabetes.

55 th lower ejection fraction or diagnosed with diabetes.

56 ular events, but did reduce the incidence of diabetes.

57 y using MRI in overweight adults with type 2 diabetes.

58 ed in persons with type 1 diabetes or type 2 diabetes.

59 6-75 years], respectively), mean duration of diabetes (10 years [range, 1-25 years] vs 10 years [rang

60 ugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extensively a

61 associated with an increased risk of type 2 diabetes affect the function of a monocarboxylate transp

62 In 1,259 type 2 diabetes-affected case subjects and 5,765 control subjec

63 point trial, consenting patients with type 2 diabetes aged >18 years, with waist circumference >94 (m

64 to patients without diabetes, patients with diabetes also had a lower Atrial Fibrillation Effects on

65 mitochondrial dysfunction observed in type 1 diabetes alters mitochondrial ATP and IFNgamma productio

66 ; Me-Can, P trend = 0.04) and pre-diagnostic diabetes (AMORIS, HR = 0.30, 95% CI 0.17 to 0.53).

67 ion has been associated with incident type 2 diabetes and atherosclerotic cardiovascular disease.

68 egion harboring a previously reported type 1 diabetes and autoimmune disorder locus.

69 association among these precursors of type 2 diabetes and cognitive dysfunction.

70 al adiposity has been associated with type 2 diabetes and coronary heart disease (CHD).

71 es of the association between pregestational diabetes and each CHD phenotype with previous estimates.

72 INTERPRETATION: Patients with diabetes and HFrEF enrolled in PARADIGM-HF who received

73 We evaluated the association between diabetes and incidence of total knee replacement (TKR) d

74 Type 2 diabetes and insulin resistance are associated with redu

75 arsenic exposure and metabolism with type 2 diabetes and insulin resistance.

76 thy (DN) is one of vascular complications of diabetes and is caused by abnormal protein kinase C acti

77 ethionine and BCAAs, in patients with type 2 diabetes and NAFLD.

78 ciated with Alzheimer's, Parkinson's, type 2 diabetes and prion diseases.

79 S-beta-cells for cell replacement for type 1 diabetes and provide proof of principle for therapeutic

80 The synergy of diabetes and SM16 in altering gene expression was not ob

81 mference, and lower odds of hypertension and diabetes) and an unfavorable profile (higher LDL cholest

82 alysis of prospective cohort studies (type 2 diabetes), and a prospective cohort study (dental caries

83 ng Alzheimer and Parkinson diseases, type II diabetes, and a number of systemic amyloidoses.

84 diseases, including cardiovascular disease, diabetes, and cancer.

85 seases such as systemic lupus erythematosus, diabetes, and cancer.

86 covariates: race, education, smoking status, diabetes, and cardiovascular disease.

87 with AZD1480 were protected from autoimmune diabetes, and diabetes was reversed in newly diagnosed N

88 HTN, diabetes, and dyslipidemia have independent and dose-res

89 ed in the beta cells of patients with type 2 diabetes, and in the beta cells of obese diabetic rodent

90 for body mass index, smoking, hypertension, diabetes, and systemic steroid use.

91 lomerular endothelial cells after 3 weeks of diabetes, and these accumulated over time in addition to

92 index >/=30, current smoking, hypertension, diabetes, and total cholesterol >/=200 mg/dL) were evalu

93 risk factor (hypertension, dyslipidemia, or diabetes) (aOR, 6.54 [95% CI, 1.87-22.88]).

94 ntal evidence suggests that individuals with diabetes are at increased risk of infection.

95 Obesity and type 2 diabetes are significant risk factors for malignancies,

96 nd comorbidities in contemporary youth-onset diabetes are unknown.

97 de on renal outcomes in patients with type 2 diabetes are unknown.

98 Comorbidities, specifically obesity and diabetes, are previously unidentified risk factors for s

99 Our study does not support diabetes as a risk factor of KOA.

100 tailored management of patients with type 2 diabetes, as has been shown in patients with maturity on

101 The modest increased risk of diabetes associated with hysterectomy may be due to resi

102 diabetes reduced the cumulative incidence of diabetes-associated autoantibodies.

103 d participate in pore formation are e, f, g, diabetes-associated protein in insulin-sensitive tissues

104 ere hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity

105 g Adults study, aged 18 to 30 years, without diabetes at baseline (1985-1986; N = 4251) were observed

106 patients in the surgery group who had type 2 diabetes at baseline, type 2 diabetes remitted in 66 of

107 nt (previously diagnosed or screen-detected) diabetes at baseline, with an overall incidence rate of

108 es consistently in patients with and without diabetes at baseline.

109 In addition, compared with participants with diabetes but without DR, those with mild (OR, 1.81; 95%

110 High arsenic exposure has been related to diabetes, but at low-moderate levels the evidence is mix

111 as part of lifestyle intervention in type 2 diabetes, but further randomized studies are warranted.

112 To provide national estimates of undiagnosed diabetes by using a confirmatory testing strategy, in li

113 ol of blood glucose (BG) would revolutionize diabetes care.

114 lief is that one quarter to one third of all diabetes cases remain undiagnosed.

115 During 7 y of follow-up, 9,504 new diabetes cases were recorded among 482,591 participants

116 By 16S rRNA sequencing, we show here that diabetes causes a shift in oral bacterial composition an

117 sting HIV infection, tuberculosis infection, diabetes, chronic respiratory disease, and blindness hea

118 HbA1c and bodyweight in patients with type 2 diabetes compared with placebo, and showed a similar saf

119 iduals are twice as likely to develop type 2 diabetes compared with white individuals, and these disp

120 ariation in protein levels that arise due to diabetes contribute to different VSMC behavior and thus

121 Our review shows that although the Diabetes Conversation Map program holds the potential to

122 Since beta cell dysfunction occurs during diabetes development, it was not clear how human islets

123 m at 1 year according to diabetes status (no diabetes, diabetes without insulin therapy, diabetes on

124 Among adults with type 2 diabetes diagnosed for less than 10 years, a lifestyle i

125 neighborhood characteristics and obesity and diabetes diagnoses (Type 1 and Type 2).

126 an eye examination by 6 years after initial diabetes diagnosis (net worth of >/=$500000 vs <$25000:

127 ted that in nutrition label users, the HR of diabetes diagnosis risk decreased significantly with tim

128 cal characteristics available at the time of diabetes diagnosis.

129 The majority of individuals with type 1 diabetes do not meet recommended glycemic targets.

130 cator of CHD and ASCVD after controlling for diabetes duration of 10 years or longer at baseline, ins

131 e poorest individuals for arthritis, asthma, diabetes, edentulism, and >/=4 chronic conditions.

132 everal risk factors of upper limb ischemia - diabetes, end-stage renal failure, hyperparathyroidism,

133 ths 21 years or younger with newly diagnosed diabetes enrolled in a US managed care network from Janu

134 We hypothesized that individuals with more diabetes genetic risk alleles have a higher risk of deve

135 Finally, monocytes from patients with type 2 diabetes had increased Mll1 compared with control subjec

136 Diabetes has long been seen as one of the first applicat

137 pment of cancer, cardiovascular disease, and diabetes has not been formally and comprehensively revie

138 Studies in animal models of type 2 diabetes have shown that glucagon-like peptide 1 (GLP-1)

139 Compared to subjects without diabetes, hazard ratio (HR) of TKR for subjects with dia

140 Age, duration of diabetes, HbA1c, BMI, BCVA, and CST had no impact on the

141 l treatment options are available for type 2 diabetes; however, many patients do not achieve optimum

142 g, year of delivery, maternal pregestational diabetes, hypertension, and psychiatric disorders.

143 ith established metabolic syndrome (MetS) or diabetes identifies CHD and ASCVD prognostic indicators

144 s 48.6% for prediabetes and 3.8% vs 7.3% for diabetes in 572 observations from participants with SCT

145 increases the susceptibility for developing diabetes in a sex-dependent manner.

146 ppressive phenotype and delayed the onset of diabetes in NOD mice.

147 alpingo-oophorectomy (BSO), and incidence of diabetes in postmenopausal women participating in the Wo

148 this protective mechanism may contribute to diabetes in states of glucocorticoid excess, such as Cus

149 ly the relationship between hypertension and diabetes in the adult-parent dyads was statistically sig

150 rt the key autophagy regulators modulated by diabetes in the murine developing neuroepithelium.

151 ed baseline data from 3,987 subjects without diabetes in the Progression of Early Subclinical Atheros

152 drug target for insulin resistance in Type-2 diabetes, in which the unmet therapeutic need remains su

153 Prkca gene, which encodes PKCalpha, reverses diabetes-induced autophagy impairment, cellular organell

154 ed with a P2X7 inhibitor were protected from diabetes-induced TNF-alpha, IL-1beta, ICAM-1, and NOS2 u

155 Diabetes-induced visual dysfunction is associated with s

156 Type 1 diabetes is a challenging condition to manage for variou

157 CGM during pregnancy in patients with type 1 diabetes is associated with improved neonatal outcomes,

158 Type 1 diabetes is characterized by the loss of insulin product

159 Type 2 diabetes is often accompanied by dyslipidemia with eleva

160 Type 1 diabetes is typically considered a disease of children a

161 In diabetes, macrophages display a prolonged inflammatory p

162 -sectional clinic-based study, the Singapore Diabetes Management Project, was conducted from December

163 al relationship, periodontal destruction and diabetes may be independent risk factors for all-cause a

164 imbalance in chronic diseases such as type-1 diabetes may lead to detectable perturbations in the mol

165 to inflammation as one of the key players in diabetes-mediating adverse effects to the neuronal and v

166 Diabetes mellitus (DM) is associated with increased mort

167 ve been associated with an increased risk of diabetes mellitus (DM), whereas the association with art

168 le of iron in the development of gestational diabetes mellitus (GDM), a common pregnancy complication

169 examined the association between gestational diabetes mellitus (GDM), a state of transient hyperglyce

170 ired glucose tolerance (IGT) and gestational diabetes mellitus (GDM), and we used linear regression m

171 Erythrocytes in patients with type-2 diabetes mellitus (T2DM) are associated with reduced cel

172 In type 2 diabetes mellitus (T2DM) patients (n = 38), the levels o

173 drug candidates for the treatment of Type 2 diabetes mellitus (T2DM).

174 ads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM).

175 ary atherosclerosis in prediabetes and early diabetes mellitus among men.

176 econdary prevention care among patients with diabetes mellitus and cardiovascular disease, which in t

177 ficantly improves outcomes for patients with diabetes mellitus and cardiovascular disease.

178 bidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease

179 among 13 616 patients from 38 countries with diabetes mellitus and known cardiovascular disease at en

180 linical indications, including patients with diabetes mellitus and prediabetes and those with high ri

181 Patients with type 2 diabetes mellitus and prior cardiovascular events had hi

182 Anonymized data of 50 254 patient eyes with diabetes mellitus at 19 UK hospital eye services were ex

183 of HealthLNK for hypertension, obesity, and diabetes mellitus diagnosis by using International Class

184 g diabetes mellitus in NET patients, whereas diabetes mellitus does not appear to increase the mortal

185 eline, of whom 67% had a diagnosis of type 2 diabetes mellitus for >10 years, 58% were receiving insu

186 h preserved ejection fraction, patients with diabetes mellitus have more signs of congestion, worse q

187 re tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12h.

188 Diabetes mellitus in early pregnancy can cause neural tu

189 ot appear to increase the risk of developing diabetes mellitus in NET patients, whereas diabetes mell

190 concentrations of glyoxal are elevated in in diabetes mellitus patients compared to nondiabetics.

191 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

192 mly assigned 10 142 participants with type 2 diabetes mellitus to canagliflozin or placebo.

193 rm mortality among patients with undiagnosed diabetes mellitus was high compared to patients without

194 panning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk, repre

195 okine abnormalities (the hallmarks of type 2 diabetes mellitus) are characteristic features of heart

196 ors (hypercholesterolemia, hypertension, and diabetes mellitus).

197 ristics were similar between groups: 50% had diabetes mellitus, 41% were women, mean lesion length wa

198 ed beta-cell dysfunction and death in type 1 diabetes mellitus, although the mechanisms are incomplet

199 tes, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease.

200 on clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, a

201 and control groups in terms of hypertension, diabetes mellitus, ischaemic heart disease and hyperlipi

202 clude sedentary lifestyle, smoking, obesity, diabetes mellitus, obstructive sleep apnea, and elevated

203 LBH gene variants are associated with type I diabetes mellitus, systemic lupus erythematosus, RA, and

204 Compared with those without diabetes mellitus, they were more likely to have a histo

205 e of liver disease, liver-related death, and diabetes mellitus, whereas the other conditions studied

206 ilure at time of transplant, with or without diabetes mellitus.

207 lence of elevated predicted cardiac risk and diabetes mellitus.

208 llitus was high compared to patients without diabetes mellitus.

209 risk factors for cardiovascular disease and diabetes mellitus.

210 (HbA1c) is accordingly examined for checking diabetes mellitus.

211 etic retinopathy is a common complication of diabetes mellitus.

212 ncountered by patients suffering from type 2 Diabetes Mellitus.

213 y and contribute to microvascular disease in diabetes mellitus.

214 consumption in people with type 1 and type 2 diabetes mellitus.

215 the potential to attenuate hyperglycemia in diabetes mellitus.

216 and ASCVD using CAC scores among those with diabetes, MetS, or neither condition.

217 Longstanding diabetes might increase the risk of acute rejections.

218 ed with age-matched control subjects without diabetes (n = 26; mean age = 7.43 years; 14 females).

219 lated patients with AF, the sole presence of diabetes not requiring insulin did not imply an increase

220 Ascites, liver disease, diabetes, obesity, and primary suture repair without mes

221 tributes to a variety of diseases, including diabetes, obesity, neurodegenerative disorders, aging, a

222 obstructive pulmonary disease, hypertension, diabetes, obesity, percent of population 65 years of age

223 Diabetes occurred in the anti-CSF-1 receptor protected m

224 (HNF-1A) are associated with maturity-onset diabetes of the young form 3 (MODY 3) and type 2 diabete

225 s been shown in patients with maturity onset diabetes of the young.

226 diabetes, diabetes without insulin therapy, diabetes on insulin therapy).

227 apy-induced tolerance in mice with new-onset diabetes on the presence and functionality of CD4(+)Foxp

228 tis B core antigen+, and less likely to have diabetes or hypertension.

229 ing heart failure is higher in patients with diabetes or obesity, even with optimal medical treatment

230 n extensively studied in persons with type 1 diabetes or type 2 diabetes.

231 thy related to human immunodeficiency virus, diabetes, or Fabry disease) can be evaluated with a skin

232 In human type 1 diabetes pancreatic islets, fasting conditions reduce PK

233 BMI over 25 kg/m(2), diabetes, past and current smoking, red meat consumption

234 xclusively identified in the serum of type 2 diabetes patients.

235 Compared to patients without diabetes, patients with diabetes also had a lower Atrial

236 Increased understanding of specific diabetes phenotypes and genotypes might result in more s

237 The use of DAPT in patients with diabetes post-CABG in our cohort was high.

238 CRP level was positively correlated with diabetes prevalence and levels of fasting and 2-hour glu

239 Because diabetes prevalence is increasing and may be on the caus

240 matching for age, sex, hypertension, type 2 diabetes, previous stroke, and anticoagulation, incident

241 y challenging to study this parameter during diabetes progression.

242 Among adolescents with type 1 diabetes, rapid increases in albumin excretion during pu

243 2 diabetic rats but not in rats with type 1 diabetes receiving insulin supplementation that did not

244 e effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin.

245 fants with genetic susceptibility for type 1 diabetes reduced the cumulative incidence of diabetes-as

246 ed Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Regi

247 om the Kaiser Permanente Northern California Diabetes Registry (n = 434,806 person-years; 2007-2010).

248 flow and other pathophysiological aspects of diabetes-related vascular complications.

249 uced the cytotoxicity of human-origin type 1 diabetes-relevant autoreactive CD8(+) T cells.

250 f malformations in pregnancies in women with diabetes remain poorly identified.

251 who had type 2 diabetes at baseline, type 2 diabetes remitted in 66 of 88 patients (75%) at 2 years,

252 sylation may provide important insights into diabetes research and therapeutic treatments.

253 A key goal of diabetes research is to develop treatments to safely pro

254 demonstrated to be a promising approach for diabetes reversal in NOD mice.

255 ly pathogenic and showed no association with diabetes risk (combined minor allele frequency [MAF] 0.2

256 ironmental determinants of type 1 and type 2 diabetes risk and progression, as well as complications.

257 We found that the diabetes risk genotype C/C at rs13266634 is associated w

258 association between nutrition label use and diabetes risk in the longer term.

259 to be associated with insulin resistance and diabetes risk.

260 bolism with B vitamins and AS3MT variants on diabetes risk.

261 sion was used to estimate HRs and 95% CIs of diabetes risk.In 494,741 person-years of follow-up, 5207

262 logy of a syndrome characterized by neonatal diabetes, sensorineural deafness, and congenital catarac

263 unique associations between published type 2 diabetes single nucleotide polymorphisms (SNPs) and geno

264 oke/systemic embolism at 1 year according to diabetes status (no diabetes, diabetes without insulin t

265 isk factors, a latent variable for glycemia (diabetes status, fasting glucose, glycated hemoglobin (H

266 Type 1 diabetes (T1D) manifests when the insulin-producing panc

267 ded by Tnfrsf9) deficiency suppressed type 1 diabetes (T1D) progression in NOD mice.

268 ations isolated from 81 subjects with type 1 diabetes (T1D).

269 early features in the pathogenesis of type 1 diabetes (T1D).

270 in islet mass in different stages of type 2 diabetes (T2D) as measured by noninvasive imaging is cur

271 Type 2 diabetes (T2D) has many cardiovascular complications, in

272 cohort studies, while the relation to type 2 diabetes (T2D) in the elderly remains unclear.

273 ect of Copy Number Variants (CNVs) on Type 2 Diabetes (T2D) remains little explored.

274 beta-Cell failure in type 2 diabetes (T2D) was recently proposed to involve dediffer

275 tide (IAPP), which is associated with type 2 diabetes (T2D), with the Alzheimer's disease amyloid-bet

276 ng DBA2/J and Nos3 (eNos) KO mouse models of diabetes, TEPP-46 treatment reversed metabolic abnormali

277 aturated and animal fat had a higher risk of diabetes than the lowest quartile (HR: 2.19; 95% CI: 1.2

278 ck women and men were more likely to develop diabetes than white men and women (black women: HR, 2.86

279 ides a starting point for the development of diabetes therapeutics that are devoid of the blood press

280 peptidase-4, a protease that is a target of diabetes therapies.

281 milarly in individuals with T2DM and without diabetes to <40 mg/dL, which is well below the normal fa

282 could combat the transmission of obesity and diabetes to subsequent generations.

283 Type 1 diabetes treated with insulin pump therapy or with multi

284 nerate an unlimited supply of beta cells for diabetes treatment.

285 ic-related air pollution on the incidence of diabetes using a population-based cohort in British Colu

286 ulin infusion; CSII) in patients with type 1 diabetes using continuous glucose monitoring (CGM) has n

287 , hazard ratio (HR) of TKR for subjects with diabetes was 0.63 [95% confidence interval (CI), 0.52-0.

288 lpha-deficient (DGKalpha(-/-)) mice in which diabetes was induced by streptozocin.

289 were protected from autoimmune diabetes, and diabetes was reversed in newly diagnosed NOD mice.

290 In our meta-analysis, pregestational diabetes was significantly associated with each CHD phen

291 The prevalence of prediabetes and diabetes was statistically significantly lower among par

292 lity genotypes for celiac disease and type 1 diabetes were followed up for up to 20 years for develop

293 prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve

294 738 in the placebo group were diagnosed with diabetes while on treatment.

295 itive function in older patients with type 2 diabetes who are carriers of the haptoglobin (Hp) 1-1 ge

296 a among 1787 adult patients with type 1 or 2 diabetes who received primary care at the clinics and ob

297 rate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density

298 c islets, results in glucose intolerance and diabetes without affecting insulin sensitivity.

299 r according to diabetes status (no diabetes, diabetes without insulin therapy, diabetes on insulin th

300 [yes or no], current smoker [yes or no], and diabetes [yes or no]), and their associations with indiv